SHH and medulloblastoma: More recently, the management of medulloblastoma has been revolutionized by advancements in tumor molecular characterization, moving from previous risk definitions based on amount of residual disease, age, and presence of metastatic disease to current stratifications based on molecular subgroups: WNT, sonic hedgehog (SHH), Group 3, and Group 4.